Needham raises Veeva stock price target to $300, maintains buy

On Thursday, Needham & Company updated its outlook for Veeva Systems (NYSE:VEEV), increasing the price target to $300 from the previous $270 while reiterating a Buy rating on the company’s shares. The adjustment follows Veeva’s robust performance at the outset of FY26, prompting the company to revise its guidance upwards.

Analysts at Needham expressed continued confidence in Veeva’s business trajectory, especially in light of its successful transition to the Vault platform. The company anticipates that over 200 customers will have gone live on Vault by the time of its summit next spring. The firm’s analysts noted that, despite Salesforce (NYSE:CRM)’s recent success in securing a CRM deal with Takeda, Veeva’s execution on Vault conversions remains strong. They also suggested that the bespoke solutions Salesforce offers to companies like Takeda might eventually be deemed too expensive, potentially leading to Veeva regaining competitive ground. InvestingPro data reveals that Veeva holds more cash than debt and maintains excellent liquidity with a current ratio of 4.5, suggesting strong financial flexibility to support its growth initiatives.

The report highlighted that Veeva’s commercial segment, including Crossix, and various components of its R&D suite are performing well, contributing to the company’s overall strong results. The analysts believe that the concerns raised by Salesforce’s announcements are likely to present additional buying opportunities for investors, reinforcing the recommendation to purchase Veeva stock for its long-term prospects.

Needham’s analysts concluded that Veeva’s consistent execution across its business, including areas beyond CRM, supports a positive outlook for the company. Despite potential market concerns, they maintain that Veeva’s strategic moves and product development are on track to deliver value, justifying the raised price target and the continued endorsement of the stock. With a P/E ratio of 53.1 and an "GREAT" Financial Health score from InvestingPro, Veeva demonstrates both premium valuation and solid fundamentals.

In other recent news, Veeva Systems reported impressive first-quarter earnings, with a notable earnings per share (EPS) of $1.97, surpassing analyst expectations by $0.23. The company’s revenue reached $759 million, exceeding the consensus estimate of $728.32 million, marking a 17% increase from the same quarter last year. Subscription revenue grew by 19% year-over-year, contributing significantly to the overall financial success. The robust performance has led Veeva to provide an optimistic financial outlook for the second quarter and fiscal year 2026, with projected EPS of $7.63 and revenue between $3.09-3.1 billion, both above consensus estimates.

Analyst firms responded by adjusting their price targets for Veeva Systems. Stifel increased the target to $295, maintaining a Buy rating, while Raymond (NSE:RYMD) James raised it to $310 with an Outperform rating. BofA Securities also updated its target to $304, retaining a Neutral rating. The success of Veeva’s Crossix unit, known for healthcare marketing analytics, played a key role in these positive assessments. Additionally, Veeva has introduced new initiatives such as Veeva AI and Veeva CRM Pulse, aimed at enhancing productivity and data offerings in the life sciences sector.

These developments underscore Veeva Systems’ strategic importance in the pharmaceutical industry, as highlighted by Raymond James, which believes the company is well-positioned to withstand broader market volatility. Despite the challenging macroeconomic environment, Veeva’s strong execution and innovative solutions continue to drive growth and investor confidence.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.